Find News

Filter articles

Applied Filters

Showing 71 to 80 of 649 results

EU court throws out dentistry TM application


The EU General Court has dismissed an appeal from German company Nemius Group against a decision to refuse registration for its ‘Dentaldisk’ mark.

UK could lose out on Europe-wide drug safety system post-Brexit

EU, UK12-02-2019

UK patients could be more exposed to counterfeit medicines than EU patients in the event of a ‘no deal’ Brexit, because access to an initiative aimed at protecting patients from fake drugs could be lost.

GSK and Merck KGaA unite in €3.7bn immunotherapy deal

Germany, UK06-02-2019

UK headquartered GSK has made another move in the oncology space, signing a potential €3.7 billion immunotherapy deal with Germany-based Merck KGaA.

Merck signs DNA licensing deal with Vertex

Germany, US28-01-2019

German pharmaceutical company Merck Group has granted US biotech firm Vertex a licence to two DNA-dependent protein kinases inhibitors.

HGF adds IP partner in The Hague office


Law firm HGF has added Leythem Wall as a partner.

Novartis enters AI partnership with Oxford University


Novartis and the University of Oxford’s Big Data Institute have joined forces to use artificial intelligence for improving drug development, initially in the areas of multiple sclerosis, dermatology and rheumatology.

Life sciences lawyers shocked and concerned amid Brexit uncertainty


Lawyers have told LSIPR they are concerned about the continuing UK political uncertainty having a negative impact on life sciences investment and the Unified Patent Court.

Sanofi collaborates with Biomunex to develop antibody therapeutics


Multinational pharmaceutical company Sanofi has entered into a licensing agreement with Paris-based biopharmaceutical company Biomunex.

UK publishes further no-deal Brexit guidance for medicines


The UK government has published further guidance on the regulation of medicines, medical devices and clinical trials in the event of a no-deal Brexit.

GSK and Pfizer sign joint venture, but will demerge after three years

International, UK, US20-12-2018

Pharmaceutical companies GSK and Pfizer yesterday announced that they will combine their consumer health businesses into a new joint venture with sales of approximately £9.8 billion ($12.7 billion).

Showing 71 to 80 of 649 results